1.4900
24-January-25 16:45:00
15 minutes delayed
Stocks
+0.1000
+7.19%
Today's range
1.3600 - 1.4900
ISIN
N/A
Source
NASDAQ
Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer
08 Feb 2021 08:00:01 By Nasdaq GlobeNewswire